Cordex Receives Special Protocol Assessment Approval From FDA For ATPace(TM)

Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process. ATPace(TM) is a novel stable liquid formulation of adenosine 5′-triphosphate (ATP).

More: continued here

Filed under: Clinical Trials on June 4th, 2009